Figure 1. Overlapping androgen receptor (AR) and glucocorticoid receptor (GR) or overlapping AR and c-Myb target genes as therapy targets for castration-resistant prostate cancer.

Recent studies point to a high priority gene set of potentially actionable therapy targets for castration-resistant prostate cancer. Anti-AR agents result in derepression of specific genes, including targets of GR and c-Myb, that function as transcriptional regulators of a subset of target genes that overlap with target genes of AR. Expression of these genes is related to adaptive drug resistance.